A Phase 3 interventional study of Aricept (donepezil SR 23 mg) and Aricept (donepezil IR 10 mg) in Alzheimer's Disease, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 45 Years to 90 Years. Per ClinicalTrials.gov, last updated 2014-07-11.
Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.
Among the 60 studies testing donepezil in Alzheimer Disease, this one has the largest enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2007, is one of 10 in phase 3, and was the 15th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
Browse Alzheimer Disease studies →2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50+
Eisai Inc.
Ages 50–85
By country, each count listing its studies:
Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →
Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.
This study: 45 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,467 is above the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.
Median enrollment 79 across the 58 interventional studies. Of the 56 that completed or were terminated, 21 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
46 studies in Alzheimer Disease by Eisai Co., Ltd.: 7 open now, 12 under way, 2 of them phase 3. Of 33 finished, 11 (33%) have results posted.
Among the 46 studies in Alzheimer Disease by Eisai Co., Ltd., this one is the 3rd largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2007, is one of 8 in phase 3, and was the 8th registered.
Eisai Co., Ltd.’s Alzheimer Disease studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing donepezil in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 46 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer's disease.
This study consists of a double-blind, double-dummy, parallel-group comparison of 23 mg donepezil SR with the currently marketed donepezil formulation (10 mg donepezil IR) in patients with moderate to severe Alzheimer's disease. Patients must have been taking 10 mg IR (or a bioequivalent generic) for at least 3 months prior to Screening. The study will consist of 24 weeks of daily administration of study medication, with clinic visits at Screening, Baseline, 3 weeks (safety only), 6 weeks, 12 weeks, 18 weeks and 24 weeks or early termination. Patients will receive either 10 mg donepezil IR in combination with the placebo corresponding to 23 mg donepezil SR, or 23 mg donepezil SR in combination with the placebo corresponding to 10 mg donepezil IR.
A total of approximately 1600 patients will be enrolled to obtain complete data from approximately 1200 completed patients (Revised per Amendment 02). During the Baseline visit, patients will be randomized in a 2:1 ratio (23 mg donepezil SR to 10 mg donepezil IR). The study will be performed at approximately 200 global sites (Asia, Oceania, Europe, India, Israel, North America, South Africa, and South America) (Revised per Amendments 01 and 02). An Independent Data Monitoring Committee (IDMC) will be established to review safety aspects of the study and to evaluate the results of a planned interim analysis.
Patients who complete the study may be eligible to undergo evaluation for enrollment into the open-label extension study, E2020-G000-328.
Inclusion Criteria for Patients:
Inclusion Criteria for Caregivers:
The designated caregiver must be sufficiently familiar with the patient (as determined by the investigator) to provide accurate data. The caregiver must have regular contact with the patient (i.e., an average of 10 or more hours per week), must be able to observe for possible adverse events, and must be able to accompany the patient to all visits.
Exclusion Criteria for Patients:
Exclusion Criteria for Caregivers:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Aricept (donepezil SR 23 mg)
Drug: Aricept (donepezil IR 10 mg)
Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design: 23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation.
Also known as: Donepezil hydrochloride
Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design: 10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation.
Also known as: Donepezil hydrochloride
Change From Baseline to Week 24 in SIB Total Score
The SIB is an assessment of cognitive dysfunction across nine domains such as memory, language, and orientation. The score ranges from 0 (worst) to 100 (best). This outcome was calculated using the LOCF (last observation carried forward) method.
Time frame: Baseline and Week 24
Overall Change From Baseline in Modified CIBIC+ to Week 24
The CIBIC+ is a rating scale derived from an interview with the patient and caregiver with an independent rater designed to measure several domains of patient function, such as mental/cognitive state, behavior, and activities of daily living. The scores range from 1 (marked improvement) to 7 (marked worsening).
Time frame: Baseline and Week 24
Change From Baseline to Week 24 in ADCS-ADL Total Score
The ADCS-ADL (Alzhemier's Disease Cooperative Study-Activities of Daily Living) is a 19-item assessment scale used to measure a patient's basic functional abilities, such as walking, grooming, and bathing.Scores range from 0 to 54, with a higher score indicating greater functional ability.
Time frame: Baseline and Week 24
Change From Baseline to Week 24 in MMSE Total Score
The MMSE (Mini-Mental State Examination) is a 30-item test that evaluates 5 domains of cognitive function (orientation to time and place, immediate and delayed recall, attention, calculation, and language). The scores range from 0 (most impaired) to 30 (no impaiment).
Time frame: Baseline and Week 24
| Milestone | Donepezil SR 23 mg | Donepezil IR 10 mg |
|---|---|---|
| Started | 981 | 486 |
| Completed | 685 | 399 |
| Not completed | 296 | 87 |
| Withdrew: Adverse event | 182 | 39 |
| Withdrew: Medication non-compliance | 9 | 4 |
| Withdrew: Protocol violation | 15 | 5 |
| Withdrew: Request of investigator or sponsor | 4 | 5 |
| Withdrew: Withdrawal by subject | 61 | 22 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Other | 24 | 12 |
The SIB is an assessment of cognitive dysfunction across nine domains such as memory, language, and orientation. The score ranges from 0 (worst) to 100 (best). This outcome was calculated using the LOCF (last observation carried forward) method.
| Scores on a scale | Donepezil SR 23 mg | Donepezil IR 10 mg |
|---|---|---|
| Change From Baseline to Week 24 in SIB Total Score | 2.6 ± 0.58 | 0.4 ± 0.66 |
The ADCS-ADL (Alzhemier's Disease Cooperative Study-Activities of Daily Living) is a 19-item assessment scale used to measure a patient's basic functional abilities, such as walking, grooming, and bathing.Scores range from 0 to 54, with a higher score indicating greater functional ability.
| Scores on a scale | Donepezil SR 23 mg | Donepezil IR 10 mg |
|---|---|---|
| Change From Baseline to Week 24 in ADCS-ADL Total Score | -1.2 ± 6.83 | -1.2 ± 6.78 |
The MMSE (Mini-Mental State Examination) is a 30-item test that evaluates 5 domains of cognitive function (orientation to time and place, immediate and delayed recall, attention, calculation, and language). The scores range from 0 (most impaired) to 30 (no impaiment).
| Scores on a scale | Donepezil SR 23 mg | Donepezil IR 10 mg |
|---|---|---|
| Change From Baseline to Week 24 in MMSE Total Score | 0.6 ± 2.93 | 0.4 ± 3.20 |
The CIBIC+ is a rating scale derived from an interview with the patient and caregiver with an independent rater designed to measure several domains of patient function, such as mental/cognitive state, behavior, and activities of daily living. The scores range from 1 (marked improvement) to 7 (marked worsening).
| Scores on a scale | Donepezil SR 23 mg | Donepezil IR 10 mg |
|---|---|---|
| Overall Change From Baseline in Modified CIBIC+ to Week 24 | 4.23 ± 1.07 | 4.29 ± 1.07 |
Collected over All adverse events (AEs) were recorded from the time of informed consent until after the Final Visit or Early Termination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Donepezil SR 23 mg | — | 80/963 (8.3%) | 233/963 (24.2%) |
| Donepezil IR 10 mg | — | 45/471 (9.6%) | 50/471 (10.6%) |
| Event | Donepezil SR 23 mg | Donepezil IR 10 mg |
|---|---|---|
| SyncopeNervous system disorders | 2/963 | 5/471 |
| AggressionPsychiatric disorders | 2/963 | 4/471 |
| PneumoniaInfections and infestations | 3/963 | 3/471 |
| Confusional statePsychiatric disorders | 1/963 | 3/471 |
| Urinary tract infectionInfections and infestations | 6/963 | 2/471 |
| FallInjury, poisoning and procedural complications | 6/963 | 2/471 |
| HypothermiaGeneral disorders | 1/963 | 2/471 |
| ConvulsionNervous system disorders | 0/963 | 2/471 |
| Atrial fibrillationCardiac disorders | 4/963 | 1/471 |
| BradycardiaCardiac disorders | 4/963 | 0/471 |
| Event | Donepezil SR 23 mg | Donepezil IR 10 mg |
|---|---|---|
| NauseaGastrointestinal disorders | 113/963 | 16/471 |
| VomitingGastrointestinal disorders | 86/963 | 12/471 |
| DiarrhoeaGastrointestinal disorders | 76/963 | 25/471 |
| AnorexiaMetabolism and nutrition disorders | 51/963 | 8/471 |
| Age, Continuous(Years) | Donepezil SR 23 mg | Donepezil IR 10 mg | Total |
|---|---|---|---|
| Mean | 73.9 ± 8.53 | 73.8 ± 8.56 | 73.8 ± 8.53 |
| Sex: Female, Male(Participants) | Donepezil SR 23 mg | Donepezil IR 10 mg | Total |
|---|---|---|---|
| Female | 607 ± 63.0 | 294 ± 62.4 | 901 ± 62.8 |
| Male | 356 ± 37.0 | 177 ± 37.6 | 533 ± 37.2 |
| Race/Ethnicity, Customized(Participants) | Donepezil SR 23 mg | Donepezil IR 10 mg | Total |
|---|---|---|---|
| Black | 22 | 9 | 31 |
| White | 708 | 346 | 1054 |
| Hispanic | 67 | 26 | 93 |
| Native American | 0 | 0 | 0 |
| Asian/Pacific | 161 | 87 | 248 |
| Other | 5 | 3 | 8 |
The record gives a start of Jun 2007 and a primary completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 3 years 8 months after primary completion. A results delay was requested in Feb 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil